SABCS 2025: Sacituzumab govitecan-hziy led to similar progression-free survival as standard of care for certain endocrine therapy-refractory advanced breast cancers
Patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancers had similar progression-free survival (PFS) whether…